Ignite Creation Date:
2024-05-05 @ 11:58 AM
Last Modification Date:
2024-10-26 @ 9:17 AM
Study NCT ID:
NCT00198354
Status:
COMPLETED
Last Update Posted:
2016-03-10
First Post:
2005-09-13
Brief Title:
Stage III NSCLC Perioperative Chemotherapy
Sponsor:
Intergroupe Francophone de Cancerologie Thoracique
Organization:
Intergroupe Francophone de Cancerologie Thoracique
Study Overview
Official Title:
Phase III Trial Comparing 2 Chemotherapy Schedules Preoperative vs Pre and Postoperative in Stage I and II NSCLC
Status:
COMPLETED
Status Verified Date:
2016-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The addition of chemotherapy to lung cancer surgery is now considered as the standard of care Solid data support postoperative chemotherapy but only few results are available in the preoperative setting To define which timing of perioperative chemotherapy offers the best survival improvement the IFCT 0002 study is conducted in France
Detailed Description:
In this multicenter study patients are randomized to receive either two preoperative chemotherapy cycles plus two additional preoperative cycles if they respond to chemotherapy or two preoperative plus two postoperative cycles in case of response
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None